Global Rheumatoid Arthritis Drugs Market (2018-2022): Expected to Register a CAGR of ~8% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Rheumatoid Arthritis Drugs Market 2018-2022”
report has been
added to ResearchAndMarkets.com’s offering.

The rheumatoid arthritis drugs market will register a CAGR of close to
8% by 2022.

The use of biologics and biosimilars for the treatment of RA is likely
to help the market grow. Unlike synthetic DMARDs, biologics have
targeted mechanisms of action and serve as promising molecules for the
successful treatment of RA.

Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs
(NSAIDs) that simply provide symptomatic relief, biologics are
considered a more effective medication for management of rheumatoid
arthritis.

Social stigma associated with RA mainly due to physical deformities and
functional limitations in RA patients. Various strategies are being
adopted to tackle social stigma at the patient level.

Market Trends

  • High cost of RA drugs
  • Use of biologics/biosimilars for treatment of RA
  • Use of gene therapy for RA treatment
  • Market dominance by TNF-alpha inhibitors
  • Need for rheumatologists

Key Players

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE

  • Segmentation by type of molecule
  • Comparison by type of molecule
  • Biologics – Market size and forecast 2017-2022
  • Small molecules – Market size and forecast 2017-2022
  • Market opportunity by type of molecule

PART 09: MARKET SEGMENTATION BY TYPE OF RA

  • Segmentation by type of RA
  • Seropositive RA
  • Seronegative RA

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • High cost of RA drugs
  • Use of biologics/biosimilars for treatment of RA
  • Use of gene therapy for RA treatment
  • Market dominance by TNF-alpha inhibitors
  • Need for rheumatologists

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma

For more information about this report visit https://www.researchandmarkets.com/research/bk8l6p/global_rheumatoid?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs
, Musculoskeletal
Disorders Drugs